NCT07681323 Timing of ctDNA Testing in Advanced Breast Cancer
| NCT ID | NCT07681323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Geneplus-Beijing Co. Ltd. |
| Condition | Advanced Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-07-08 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed advanced breast cancer * Age ≥18 years * Expected survival \>3 months * Willing to undergo ctDNA testing and sign informed consent form Exclusion Criteria: * The subject has not signed the informed consent form. * Pregnant or breastfeeding women. * Other situations deemed by the investigator as unsuitable for inclusion in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07681323 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07681323 currently recruiting?
Yes, NCT07681323 is actively recruiting participants. Contact the research team at drmafei@126.com for enrollment information.
Where is the NCT07681323 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07681323 clinical trial?
NCT07681323 is sponsored by Geneplus-Beijing Co. Ltd.. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.